04 September 2010
Keywords: Otsuka, EMEA, Abilify, Antidepresant, Schizophrenia
Article | 20 November 2009
The European Medicines Agency(EMEA) has been formally notified by Otsuka Pharmaceutical Europe, a unit of the Japanese drugmaker, of its decision to withdraw its application for an extension of indication for the centrally authorized medicine Abilify (aripiprazole) tablets, orodispersible tablets and oral solution.
A Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.